Dynamic Technology Lab Private Ltd acquired a new position in Allergan plc (NYSE:AGN) in the second quarter, HoldingsChannel.com reports. The firm acquired 1,400 shares of the company’s stock, valued at approximately $234,000.

A number of other institutional investors have also recently bought and sold shares of the stock. Thrivent Financial for Lutherans raised its holdings in Allergan by 3.1% in the first quarter. Thrivent Financial for Lutherans now owns 13,879 shares of the company’s stock worth $2,336,000 after purchasing an additional 412 shares in the last quarter. Cetera Advisor Networks LLC raised its holdings in Allergan by 80.1% in the first quarter. Cetera Advisor Networks LLC now owns 2,259 shares of the company’s stock worth $387,000 after purchasing an additional 1,005 shares in the last quarter. Brinker Capital Inc. raised its holdings in Allergan by 21.5% in the first quarter. Brinker Capital Inc. now owns 4,178 shares of the company’s stock worth $703,000 after purchasing an additional 738 shares in the last quarter. Norinchukin Bank The raised its holdings in Allergan by 1.4% in the first quarter. Norinchukin Bank The now owns 47,051 shares of the company’s stock worth $7,918,000 after purchasing an additional 649 shares in the last quarter. Finally, California Public Employees Retirement System raised its holdings in Allergan by 6.7% in the first quarter. California Public Employees Retirement System now owns 767,018 shares of the company’s stock worth $129,081,000 after purchasing an additional 48,218 shares in the last quarter. 77.33% of the stock is owned by hedge funds and other institutional investors.

Allergan stock opened at $187.98 on Tuesday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 0.85 and a current ratio of 1.00. Allergan plc has a one year low of $142.81 and a one year high of $217.00. The firm has a market cap of $64.94 billion, a P/E ratio of 11.71, a price-to-earnings-growth ratio of 1.47 and a beta of 1.21.

Allergan (NYSE:AGN) last released its quarterly earnings data on Thursday, July 26th. The company reported $4.42 EPS for the quarter, beating the consensus estimate of $4.13 by $0.29. Allergan had a positive return on equity of 8.60% and a negative net margin of 10.29%. The company had revenue of $4.10 billion for the quarter, compared to analysts’ expectations of $3.92 billion. During the same period last year, the firm posted $4.02 earnings per share. Allergan’s revenue was up 2.3% compared to the same quarter last year. equities analysts anticipate that Allergan plc will post 16.29 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Monday, September 17th. Investors of record on Friday, August 17th were given a dividend of $0.72 per share. The ex-dividend date of this dividend was Thursday, August 16th. This represents a $2.88 annualized dividend and a dividend yield of 1.53%. Allergan’s dividend payout ratio (DPR) is presently 17.61%.

In other Allergan news, Director Joseph H. Boccuzi acquired 900 shares of the company’s stock in a transaction that occurred on Thursday, August 30th. The shares were bought at an average cost of $190.59 per share, with a total value of $171,531.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Christopher J. Coughlin acquired 10,000 shares of the company’s stock in a transaction that occurred on Thursday, September 6th. The shares were acquired at an average cost of $190.64 per share, for a total transaction of $1,906,400.00. The disclosure for this purchase can be found here. Company insiders own 0.37% of the company’s stock.

AGN has been the subject of several analyst reports. TheStreet upgraded Allergan from a “d+” rating to a “c” rating in a report on Monday, August 20th. Morgan Stanley set a $202.00 price target on Allergan and gave the company an “overweight” rating in a report on Thursday, August 23rd. Zacks Investment Research upgraded Allergan from a “hold” rating to a “buy” rating and set a $193.00 price target for the company in a report on Tuesday, July 24th. Wells Fargo & Co restated a “buy” rating on shares of Allergan in a report on Saturday, September 15th. Finally, Cantor Fitzgerald set a $180.00 price target on Allergan and gave the company a “hold” rating in a report on Thursday, July 26th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and eighteen have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $211.91.

About Allergan

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories.

Featured Article: How is the S&P 500 index different from the DJIA?

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.